Stock Report

Download full stock data and analysis for free Last Updated: 07-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Neoleukin Therapeutics (NLTX) Key Ratios

Stock Card factsheet share-fund-plan-icon

$3.49

up-down-arrow $-10.47 (-75.00%)

As on 19-Dec-2023 09:30EDT

Market cap

info icon

$8 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.4

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT -81.64 59.08 36.65 16.59 2.50
Net Profit -117.07 63.89 26.72 -20.03 0.09
EPS -119.62 64.06 -34.12 -236.62 -10.96
Book Value -- -- -34.18 -16.03 -16.53
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info -509,555.91-339,747.34-----1,011,633.33
Net Margin info -244,779.20-123,563.45281,135.71---486,791.67
Return on equity info -32.40-39.76-54.63-47.23-34.97
Return on Capital info -29.89-38.18---42.72-32.53
Return on Assets info -28.45-36.15-33.99-40.13-31.26
Debt to Equity (x) info ----0.000.130.09

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
-42.72
-32.53
-14.42
-64.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-54.63

Lower than Peers by 14.30

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
-54.63
-47.23
-34.97
-14.99
-64.78
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-33.99

Lower than Peers by 2.74

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
-33.99
-40.13
-31.26
-13.96
-61.82
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

--

--

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
--
-1,011,633.33
-7,478.49
--
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

281,135.71

Higher than Peers by 281,227.01

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
281,135.71
--
-486,791.67
-2,766.74
-4,574.11
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
-1.00
-0.99
--
-1.00
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

36.65

Higher than Peers by 37.67

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
36.65
2.64
-79.96
52.47
-118.01
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

26.72

Higher than Peers by 34.25

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
26.72
4.11
-134.07
64.06
-119.84
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-34.12

Lower than Peers by 48.35

Year on year growth in earnings per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
-34.12
0.04
-1.30
0.67
-0.05
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-29.11

Lower than Peers by 18.98

Year on year growth in book value per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
-29.11
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
0.13
0.09
0.06
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.02

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
0.02
0.02
0.01
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

15.33

Higher than Peers by 9.52

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
15.33
8.96
16.67
24.66
30.28
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

15.33

Higher than Peers by 9.63

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
15.33
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-11.56

Lower than Peers by 9.47

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
-11.56
-37.36
-3,194.63
-68.83
-70,959.00
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
--
--
199.56
--
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

--

--

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
--
0.00
0.00
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
--
54,787.50
568.12
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
-0.50
-4.55
-30.58
-8.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.44

Lower than Peers by 4.89

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
0.44
0.30
1.86
3.99
4.28
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

1.07

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
1.07
0.99
-2.33
-12.25
-21.71
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

8

Lower than Peers by 134

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Neoleukin Therapeutics (NLTX)
8
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...